Brief: Dicot Pharma Resolves On Rights Issue Of About SEK 210 Mln

Dicot Pharma AB

11/05/2026 07:50

May 11 (Reuters) - Dicot Pharma AB DICOT.ST:

SAID ON FRIDAY RESOLVED ON AN 80% GUARANTEED RIGHTS ISSUE OF ABOUT SEK 210 MILLION

THE SUBSCRIPTION PRICE HAS BEEN SET AT SEK 1.36 PER UNIT, CORRESPONDING TO SEK 0.17 PER SHARE

THE SUBSCRIPTION PRICE PER SHARE CORRESPONDS TO A DISCOUNT OF APPROXIMATELY 35.9 PERCENT IN RELATION TO THE CLOSING PRICE ON MAY 7, 2026

THROUGH THE ISSUE, A MAXIMUM OF 1,236,518,456 NEW SHARES MAY BE ISSUED, RESULTING IN A DILUTION OF ABOUT 38.1%

THE PURPOSE OF THE ISSUE IS PRIMARILY TO FINANCE THE PLANNED CLINICAL PHASE 2B STUDY WITH THE DRUG CANDIDATE LIB-01

THE SUBSCRIPTION PERIOD IN THE ISSUE RUNS FROM MAY 21, 2026 THROUGH JUNE 4, 2026

TRADING IN UNIT RIGHTS WILL TAKE PLACE FROM MAY 21, 2026 THROUGH JUNE 1, 2026

 Source text for Workspace: nMFN8p1gr8
 Further company coverage: DICOT.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))